First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other

Oculis Doses First Patient in Phase 3 PIONEER-1 Trial of Privosegtor for Optic Neuritis

Key Takeaways Oculis has treated the first patient in PIONEER-1, the first of 2 registrational trials evaluating Privosegtor for acute-onset optic neuritis The study's primary endpoint is the proportion of patients gaining at least 15 letters from baseline, with the primary analysis planned for month 3 Privosegtor has received FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis, and Oculis is also planning to study the thera…